骨髓瘤代谢学的全球研究趋势和热点:跨越十年的文献计量和可视化分析
Jun-Bo Tu1,2, Tao Liu3, Jun-Feng Li3
1Department of Orthopaedics, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Frontiers in immunology
|October 24, 2024
概括
这种图书识别分析揭示了中国.
科学领域:
- 骨髓肉瘤代谢学研究.
- 科学文献的图书统计分析.
背景情况:
- 骨髓瘤是儿童和青少年常见的骨癌.
- 了解骨髓瘤代谢对于开发有效治疗方法至关重要.
研究的目的:
- 分析过去十年 (2014-2023) 骨髓瘤代谢学研究主题的演变和趋同.
- 确定该领域的关键贡献者和新兴趋势.
- 为未来的骨髓瘤代谢研究方向提供见解.
主要方法:
- 从科学网络核心收藏 (2014-2023) 中对文献进行了图书统计分析.
- 使用CiteSpace,Bibliometrix和VOSviewer进行视觉分析.
- 分析机构,期刊,国家,作者,关键词和引用.
主要成果:
- 上海通大学在出版物方面领先;国际分子科学杂志是最多产的期刊.
- 中国占据主导地位,拥有最大数量的出版物.
- 预计未来的研究将专注于瘤微环境,分子机制,自和向治疗.
结论:
- 本文献计量研究提供了关于骨髓瘤代谢研究的全面概述.
- 确定了关键趋势和热点,为未来的研究工作提供了宝贵的参考资料.
相关概念视频
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...


